The Diffuse Large B-Cell Lymphoma market growth is driven by factors like increase in the prevalence of Diffuse Large B-Cell Lymphoma, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Diffuse Large B-Cell Lymphoma market report also offers comprehensive insights into the Diffuse Large B-Cell Lymphoma market size, share, Diffuse Large B-Cell Lymphoma epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Diffuse Large B-Cell Lymphoma market size growth forward.
Some of the key highlights from the Diffuse Large B-Cell Lymphoma Market Insights Report:
- Several key pharmaceutical companies, including AbbVie and Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, AstraZeneca, Gilead Sciences, and others, are developing novel products to improve the Diffuse Large B-Cell Lymphoma treatment outlook.
- The total Diffuse Large B-Cell Lymphoma market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
- As per DelveInsight analysis, the Diffuse Large B-Cell Lymphoma market is anticipated to witness growth at a considerable CAGR
Strategize your business goals by understanding market dynamics @ Diffuse Large B-Cell Lymphoma Market Landscape
Diffuse Large B-Cell Lymphoma Overview
Diffuse Large B-Cell Lymphoma (DLBCL) is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. When you have a lymphoma, the abnormal lymphocytes build up in lymph nodes or other body organs. Each year about 5,500 people are diagnosed with DLBCL. This makes up about 40 out of 100 cases (40%) of NHL in adults. DLBCL is more common in males than females. Most people with DLBCL first notice painless lumps, often in their neck, armpit or groin. These are swollen (enlarged) lymph nodes. They usually grow quite quickly, over just a few weeks. Sometimes, DLBCL can develop in lymph nodes deep inside your body where they can’t be felt from the outside. The swollen nodes can form large lumps – known as ‘bulky disease’. DLBCL can also develop outside lymph nodes, called ‘extranodal’ disease. This affects around 1 in 5 people with DLBCL.
Diffuse Large B-cell Lymphoma Diagnosis
A tissue biopsy is needed for a definitive diagnosis of DLBCL. Because DLBCL is a blood cancer, it is important to look for any signs of lymphoma across the entire body. This is usually done with a positron emission tomography (PET) scan. A morphological diagnosis of DLBCL should be confirmed in all cases by immunophenotypic investigations, either immunohistochemistry (IHC) or flow cytometry or a combination of both techniques.
Diffuse Large B-cell Lymphoma Treatment
DLBCL treatment is typically begun shortly after diagnosis with the intent of obtaining a durable remission or cure. A combination of chemotherapy and a monoclonal antibody targeting CD20 remains the backbone of most treatments. The most widely used combination chemotherapy regimen for DLBCL is R CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) that is usually given in 21-day cycles. Sometimes etoposide (VePesid, Toposar, Etopophos) is added to the R-CHOP regimen, resulting in a drug combination called R-EPOCH. Sometimes treatment may involve radiation therapy. For many patients with DLBCL, the initial treatment can lead to disease remission (disappearance of signs and symptoms). However, for patients in whom the disease becomes refractory (no longer responds to treatment) or relapses (returns after treatment), secondary therapies may be successful.
Do you know the treatment paradigms for different countries? Download our Diffuse Large B-Cell Lymphoma Market Sample Report
Recent Breakthrough in the Diffuse Large B-Cell Lymphoma Market
FDA approves Columvi for advanced diffuse large B-cell lymphoma: The FDA granted accelerated approval to glofitamab-gxbm for treatment of certain adults with relapsed or refractory diffuse large B-cell lymphoma.
Diffuse Large B-Cell Lymphoma Epidemiology Insights:
- The total incident population of DLBCL in the 7MM comprised 73,598 cases in 2021 and are projected to increase during the forecast period.
- The total incident population of DLBCL in the United States is 29,958 in 2021.
- The United States contributed to the largest incident population of DLBCL, accounting for ~ 41% of the 7MM in 2021.
Diffuse Large B-Cell Lymphoma Epidemiology Segmentation:
DelveInsight’s Diffuse Large B-Cell Lymphoma market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Diffuse Large B-Cell Lymphoma historical patient pools and forecasted Diffuse Large B-Cell Lymphoma patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Diffuse Large B-Cell Lymphoma Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Diffuse Large B-Cell Lymphoma Prevalence
- Age-Specific Diffuse Large B-Cell Lymphoma Prevalence
- Gender-Specific Diffuse Large B-Cell Lymphoma Prevalence
- Diagnosed and Treatable Cases of Diffuse Large B-Cell Lymphoma
Visit for more @ Diffuse Large B-Cell Lymphoma Epidemiological Insights
Diffuse Large B-Cell Lymphoma Treatment Market
The Diffuse Large B-Cell Lymphoma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Diffuse Large B-Cell Lymphoma market trends by analyzing the impact of current Diffuse Large B-Cell Lymphoma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Diffuse Large B-Cell Lymphoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Diffuse Large B-Cell Lymphoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Diffuse Large B-Cell Lymphoma market in 7MM is expected to witness a major change in the study period 2019-2032.
Diffuse Large B-Cell Lymphoma Emerging Drugs
Epcoritamab: Genmab
Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology. Genmab’s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to tumors to elicit an immune response towards malignant cells. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B cells and induces T cell mediated killing of lymphoma B cells. CD20 is a clinically validated therapeutic target, and is expressed on many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia. Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies’ broad oncology collaboration. Currently, it is in phase 3 stage of development for the treatment of Diffuse Large B-Cell Lymphoma.
Glofitamab: Roche
Glofitamab is an investigational CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B-cells and CD3 on the surface of T-cells. This dual targeting activates and redirects a patient’s existing T-cells to engage and eliminate target B-cells by releasing cytotoxic proteins into the B-cells. Glofitamab is based on a novel structural format which we call ‘2:1’, which refers to the structure of the antibody. It is engineered to have two ‘Fab’ regions which bind to CD20, and one ‘Fab’ region which binds to CD3. A robust clinical development programme for glofitamab is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with CD20-positive B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma, and other blood cancers.
Acalabrutinib: Acerta Pharma
Acalabrutinib is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, acalabrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.
AUTO 3: Autolus
AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently in phase I/II stage of development for the treatment of Diffuse Large B-Cell Lymphoma.
Abexinostat: Xynomic Pharmaceuticals
Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, it is in phase 2 stage of development for the treatment of Diffuse Large B-Cell Lymphoma.
Diffuse Large B-Cell Lymphoma Key Companies
- AbbVie and Genmab
- Merck
- Roche
- Xencor and Janssen
- Denovo Biopharma
- Calithera Biosciences
- IMV
- Biogen
- Autolus Therapeutics
- Allogene Therapeutics
- Novartis
- Miltenyi Biomedicine
- Regeneron Pharmaceuticals
- Debiopharm
- Seagen
- Takeda
- AstraZeneca
- Gilead Sciences
For more information, visit Diffuse Large B-Cell Lymphoma Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Diffuse Large B-Cell Lymphoma Market Report:
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Diffuse Large B-Cell Lymphoma, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Diffuse Large B-Cell Lymphoma epidemiology in the 7MM
- Diffuse Large B-Cell Lymphoma marketed and emerging therapies
- Diffuse Large B-Cell Lymphoma companies
- Diffuse Large B-Cell Lymphoma market drivers and barriers
Key Questions Answered in the Diffuse Large B-Cell Lymphoma Market Report 2032:
- What was the Diffuse Large B-Cell Lymphoma market share distribution in 2019, and how would it appear in 2032?
- What is the total Diffuse Large B-Cell Lymphoma market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Diffuse Large B-Cell Lymphoma market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Diffuse Large B-Cell Lymphoma market projected to expand at 7MM?
Table of Contents:
1 Diffuse Large B-Cell Lymphoma Market Key Comprehensive Insights
2 Diffuse Large B-Cell Lymphoma Market Report Introduction
3 Competitive Intelligence Analysis for Diffuse Large B-Cell Lymphoma
4 Diffuse Large B-Cell Lymphoma Market Analysis Overview at a Glance
5 Executive Summary of Diffuse Large B-Cell Lymphoma
6 Diffuse Large B-Cell Lymphoma Epidemiology and Market Methodology
7 Diffuse Large B-Cell Lymphoma Epidemiology and Patient Population
8 Diffuse Large B-Cell Lymphoma Patient Journey
9 Diffuse Large B-Cell Lymphoma Treatment Algorithm, Diffuse Large B-Cell Lymphoma Current Treatment, and Medical Practices
10 Key Endpoints in Diffuse Large B-Cell Lymphoma Clinical Trials
11 Diffuse Large B-Cell Lymphoma Marketed Therapies
12 Diffuse Large B-Cell Lymphoma Emerging Therapies
13 Diffuse Large B-Cell Lymphoma: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Diffuse Large B-Cell Lymphoma
16 Diffuse Large B-Cell Lymphoma Market Key Opinion Leaders Reviews
18 Diffuse Large B-Cell Lymphoma Market Drivers
19 Diffuse Large B-Cell Lymphoma Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Diffuse Large B-Cell Lymphoma Epidemiology 2032
DelveInsight’s “Diffuse Large B-Cell Lymphoma – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Diffuse Large B-Cell Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Diffuse Large B-Cell Lymphoma Pipeline 2023
“Diffuse Large B-Cell Lymphoma Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Diffuse Large B-Cell Lymphoma market. A detailed picture of the Diffuse Large B-Cell Lymphoma pipeline landscape is provided, which includes the disease overview and Diffuse Large B-Cell Lymphoma treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/